IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09/465,133

Confirmation No. 8491

Applicant

Filed

Elisabetta Vegeto, et al

TC/AU

12/15/1999

1636

Examiner

Celine X. Qian

Docket No.

213-0041US

Customer No.

25746

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sirs and Mesdames:

Applicant desires to bring to the attention of the Examiner the following references listed on the attached Information Disclosure Statement, Form PTO 1449. A copy of each of the references is enclosed in compliance with 37 CFR § 1.97 and 1.98. Submission of this Information Disclosure Statement should not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(a) exists. This submission is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" to the invention disclosed unless specifically so designated. The right is reserved to antedate any item under 37 C.F.R. 1.131.

Authorization to charge Deposit Account No. 50-1922 is provided herewith for consideration of certain of these materials in accordance with 37 C.F.R. 1.17 (p) for submission of an Information Disclosure Statement under 37 C.F.R. 1.97(c). Should additional fees be required for the consideration of this IDS please consider this a request for consideration under the appropriate rule and an authorization for the Commissioner to charge and/ or credit should any additional fees be required or overpayment made.

Respectfully submitted.

Marilyn M. Huston, Reg. No. 37,851

WONG CABELLO LUTSCH RUTHERFORD & BRUCCULERI, LLP

20333 SH 249, Suite 600

Houston, Texas 77070

Direct (832) 446-2421, Facsimile (832) 446-2424

CERTIFICATE OF MAILING UNDER 1.11(a)

I hereby certify that this document is being deposited with the U.S. Postal Service Express Mail Service in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on January 5, 2004.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known bstitute for form 1449/PTO Application Number 09/465,133 Filing Date 12/15/1999

INFORMATION DISCLOSURE

INFORMATION		First Named Inventor	Elisabetta Vegato
STATEMENT BY APPLICANT		Art Unit	1636
(Use as many shee	ets as necessary)	Examiner Name	Celine X. Qian
Sheet 1	of 2	Attorney Docket Number	213-0041US

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 2003/0143559A1	07-31-2003	Brachen et al	
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sypostitute for form 1449/PTO		or or 1999, no persons as	o required to respond to a someonor	Complete if Known		
Sposulu	re for form 1449/PTO			Application Number	09/465,133	
INF	ORMATION	DIS	CLOSURE	Filing Date	12/15/1999	
STATEMENT BY APPLICANT		First Named Inventor	Elisabetta Vegato			
				Art Unit	1636	
(Use as many sheets as necessary)		Examiner Name	Celine X. Qian			
Sheet	2	of	2	Attorney Docket Number	213-0041US	· ·

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BOCKAMP, E, et al. Of Mice and Models: Improved Animal Models for Biomedical Research. Physiol Genomics 11: 115-132 (2002).	
		NORDSTROM, JL et al. The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids 68: 1085-1094 (2003).	
		WANG Y, et al. Ligand-inducible and liver-specific target gene expression in transgenic mice. Nature Biotechnology 15: 239 - 243 (1997).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DNOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.